Search | Clinical Trials Finder

Conditions: Diabetes Mellitus, Type 2
Interventions: Dapagliflozin, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 631 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 34
States / cities: Mesa, Arizona • Fresno, California • Greenbrae, California + 29 more

Conditions: Lipoprotein Disorder
Interventions: DII235, Saline; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 37
States / cities: Birmingham, Alabama • Huntsville, Alabama • Little Rock, Arkansas + 33 more

Conditions: HIV Infections
Interventions: BG505 SOSIP.664 gp140, adjuvanted, Placebo; Biological
Lead sponsor: International AIDS Vaccine Initiative; Network
Eligibility: 18 Years to 50 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 2
States / cities: Boston, Massachusetts • Seattle, Washington

Conditions: Myeloma
Interventions: Telephone Questionnaire; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 78 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer
Interventions: Entinostat, Atezolizumab, Placebo; Drug
Lead sponsor: Syndax Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 19
States / cities: Birmingham, Alabama • Bakersfield, California • Fullerton, California + 15 more

Conditions: Rheumatoid Arthritis
Interventions: VX-509, VX-509 matching placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 359 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 31
States / cities: Birmingham, Alabama • Huntsville, Alabama • Long Beach, California + 28 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Semaglutide, Placebos; Drug
Lead sponsor: Sabyasachi Sen; Other
Eligibility: 20 Years to 90 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 2
States / cities: Washington D.C., District of Columbia

Conditions: 2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection, 2019-nCoV Disease, 2019-nCoV Infection, COVID-19, COVID-19 Pandemic, COVID-19 Virus Disease, COVID-19 Virus Infection, Covid19, Coronavirus Disease 2019, SARS-CoV2 Infection, SARS-CoV-2 Acute Respiratory Disease
Interventions: Famotidine, Celecoxib, Placebo; Drug
Lead sponsor: Leidos Life Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 15
States / cities: Newport Beach, California • Miami, Florida • Atlanta, Georgia + 12 more

Conditions: Diabetic Gastroparesis, Idiopathic Gastroparesis
Interventions: TAK-906 Maleate, Placebo; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 67
States / cities: Dothan, Alabama • Tucson, Arizona • Chula Vista, California + 54 more

Conditions: Lumbar Spine Degeneration, Cervical Spine Degeneration
Interventions: saline 0.9%, (0.05% chlorhexidine gluconate (CHG) in sterile water); Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Bipolar Disorder
Interventions: Seroquel®, quetiapine fumarate (atypical antipsychotic), lithium (mood stabilizer), divalproex (mood stabilizer); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 710 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 81
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 78 more

Conditions: Metabolically Healthy Obesity
Interventions: Inulin Supplementation, Maltodextrin (Placebo), High-fat meal; Dietary Supplement · Other
Lead sponsor: Ball State University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Muncie, Indiana

Conditions: Keratoconjunctivitis Sicca
Interventions: Omega-3 Fatty Acid, Soybean Soft Gels; Dietary Supplement
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Recurrent Bacterial Vaginosis
Interventions: Vaginal microbiome transplant, Oral Metronidazole, Sterile saline; Biological · Drug · Other
Lead sponsor: Douglas Kwon; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Rosacea
Interventions: Anatabloc Cream, Placebo Cream; Other
Lead sponsor: Rock Creek Pharmaceuticals, Inc.; Industry
Eligibility: 25 Years to 70 Years
Enrollment: 117 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 3
States / cities: Bradenton, Florida • New Orleans, Louisiana • New York, New York

Conditions: Pandemic Influenza Immunization, Healthy Volunteers
Interventions: Pandemic flu H5 HA mRNA SD2 vaccine, Placebo; Biological · Other
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 720 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 13
States / cities: La Mesa, California • DeLand, Florida • Lakeland, Florida + 10 more

Conditions: Vitamin D Deficiency, Sarcopenia
Interventions: vitamin D3, Placebo; Dietary Supplement · Other
Lead sponsor: Tufts University; Other
Eligibility: 60 Years to 85 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Multiple Sclerosis
Interventions: Strategy-Based Training to Enhance Memory (STEM), Placebo control exercises; Behavioral
Lead sponsor: Kessler Foundation; Other
Eligibility: 18 Years to 59 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 2
States / cities: East Hanover, New Jersey • Marlton, New Jersey

Conditions: Healthy
Interventions: Ad26.ZEBOV 5*10^10 viral particles (vp), Ad26.ZEBOV 2*10^10 (vp), Ad26.ZEBOV 0.8*10^10 (vp), MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.], MVA-BN-Filo 5*10^7 Inf. U., Placebo; Biological
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 525 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 6
States / cities: Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more

Conditions: Lupus Erythematosus, Systemic
Interventions: Cenerimod, Placebo; Drug
Lead sponsor: Viatris Innovation GmbH; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 470 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 22
States / cities: Huntington Park, California • Aurora, Colorado • Clearwater, Florida + 16 more

Conditions: ADHD
Interventions: PRC-063 oral capsules, Placebo oral capsules; Drug
Lead sponsor: Purdue Pharma, Canada; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 8
States / cities: Bradenton, Florida • Lakeland, Florida • Maitland, Florida + 5 more

Conditions: HIV Preexposure Prophylaxis
Interventions: ISL, FTC/TDF, FTC/TAF, Placebo to ISL, Placebo to FTC/TDF, Placebo to FTC/TAF; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 16 Years and older · Male only
Enrollment: 494 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 15
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 11 more

Conditions: Depressive Disorder, Treatment-Resistant, Treatment Resistant Depression (TRD)
Interventions: Ketamine, Normal Saline; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Plaque Psoriasis
Interventions: Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045%, Duobrii® Lotion (Halobetasol propionate and tazarotene lotion), 0.01%/0.045%, Placebo; Drug
Lead sponsor: Sun Pharmaceutical Industries, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 402 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Charlotte, North Carolina

Search by objective public record fields.

Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment

A Study of DII235 in Adults With Elevated Lipoprotein(a)

A Randomized, Double-blinded, Placebo-controlled, Dose-escalation Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV Envelope Protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in Healthy, HIV-1 Uninfected Adults

Long-Term Follow Up Study for AMD3100 Patients

Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

Impact of Semaglutide on CD34+ EPC and Fat Derived MSC

Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients

A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants With Symptomatic Idiopathic or Diabetic Gastroparesis

Randomized Controlled Trial Comparing Irrisept Versus Normal Saline for Wound Irrigation After Posterior Spine Surgery

Efficacy and Safety of Seroquel Plus Mood Stabilizer in the Maintenance of Bipolar I Disorder

Gut, Immune, and Vascular Health in Metabolically Healthy Obesity

Omega-3 Fatty Acid Supplements and Dry Eye

Vaginal Microbiota Transplant

A Study to Evaluate the Safety, Tolerability, and Effects of Anatabloc® Crème in Rosacea

Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and Older

Impact of Vitamin D on 25-hydroxyvitamin D Levels and Physical Function

Evaluation of a Theory-Driven Manualized Approach to Improving New Learning and Memory in MS

A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants

A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus

PRC-063 Adult Laboratory Classroom Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Are at High Risk for HIV-1 Infection (MK-8591-024)

Intravenous Ketamine for Treatment-Resistant Depression

A Study Comparing Halobetasol Propionate and Tazarotene Topical Lotion 0.01%/0.045% to Duobrii® Lotion (Halobetasol Propionate and Tazarotene Lotion), 0.01%/0.045% (Reference Listed Drug) in the Treatment of Moderate to Severe Plaque Psoriasis.